{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:46:14Z","timestamp":1788975974966,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtct.2025.01.002","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T17:47:35Z","timestamp":1736272055000},"page":"257.e1-257.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Everolimus with or without Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Children with Acute Kidney Injury: A Single-Center Retrospective Analysis"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-4841","authenticated-orcid":false,"given":"Felix","family":"Zirngibl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5946-7137","authenticated-orcid":false,"given":"Pimrapat","family":"Gebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Materne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5337-5605","authenticated-orcid":false,"given":"Michael","family":"Launspach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"K\u00fcnkele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hundsdoerfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cyrull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-4893","authenticated-orcid":false,"given":"Hedwig E.","family":"Deubzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn-Sven","family":"K\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Eggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Oevermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"von Stackelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.01.002_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bmt.1705265","article-title":"Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe","volume":"37","author":"Ljungman","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0002","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/pbc.24559","article-title":"Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review","volume":"60","author":"Mateos","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2025.01.002_bib0003","doi-asserted-by":"crossref","first-page":"e13158","DOI":"10.1111\/petr.13158","article-title":"Transplant-related mortality and survival in children with malignancies treated with allogeneic hematopoietic stem cell transplantation. A multicenter analysis","volume":"22","author":"Zaucha-Prazmo","year":"2018","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2007.12.487","article-title":"Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation","volume":"14","author":"Matthes-Martin","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bbmt.2016.03.014","article-title":"Acute kidney injury and the risk of mortality in children undergoing hematopoietic stem cell transplantation","volume":"22","author":"Kizilbash","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0006","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bbmt.2017.11.021","article-title":"Acute kidney injury in pediatric patients receiving allogeneic hematopoietic cell transplantation: incidence, risk factors, and outcomes","volume":"24","author":"Koh","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.jtct.2025.01.002_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.632263","article-title":"Continuous renal replacement therapy: a review of use and application in pediatric hematopoietic stem cell transplant recipients","volume":"11","author":"Elbahlawan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0008","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.01.002_bib0009","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.01.002_bib0010","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jtct.2023.12.084","article-title":"Graft vs host disease (GVHD) in pediatric hematopoietic stem cell transplant (HCT) recipients and impact on overall survival: a CIBMTR analysis","volume":"30","author":"Nishitani","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.01.002_bib0011","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/tri.13601","article-title":"Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations","volume":"33","author":"Lawitschka","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.jtct.2025.01.002_bib0012","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.01.002_bib0014","first-page":"853","article-title":"Glomerulotubular function in cyclosporine-treated rats. A lithium clearance, occlusion time\/transit time and micropuncture study","volume":"21","author":"Dieperink","year":"1985","journal-title":"Proc Eur Dial Transplant Assoc Eur Ren Assoc"},{"key":"10.1016\/j.jtct.2025.01.002_bib0015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0016","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/sj.bmt.1701027","article-title":"Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation","volume":"20","author":"Woo","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0017","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.002_bib0018","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtct.2025.01.002_bib0020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.01.002_bib0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/cmi.2014.24","article-title":"Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation","volume":"12","author":"Vitiello","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2025.01.002_bib0023","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/annonc\/mdu021","article-title":"Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0024","first-page":"34","article-title":"Sirolimus, but not everolimus, enhances tacrolimus nephrotoxicity in the rat","author":"Christians","year":"2010","journal-title":"Am J Transplant"},{"issue":"suppl 3)","key":"10.1016\/j.jtct.2025.01.002_bib0025","article-title":"Everolimus in clinical practice\u2013renal transplantation","volume":"21","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0026","doi-asserted-by":"crossref","first-page":"e48063","DOI":"10.1371\/journal.pone.0048063","article-title":"Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat","volume":"7","author":"Bohra","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2025.01.002_bib0027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbmt.2008.11.004","article-title":"Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial","volume":"15","author":"Platzbecker","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0028","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00277-021-04487-y","article-title":"A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT","volume":"100","author":"Sch\u00e4fer","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0029","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.002_bib0030","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2212NIH\u2212CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.jtct.2025.01.002_bib0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med"},{"key":"10.1016\/j.jtct.2025.01.002_bib0032","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0033","series-title":"R: A language and environment for statistical computing","year":"2017"},{"key":"10.1016\/j.jtct.2025.01.002_bib0034","article-title":"Retrospective analysis of veno-occlusive disease\/sinusoidal obstruction syndrome in paediatric patients undergoing hematopoietic cell transplantation -a multicentre study","volume":"33:100728","author":"Ragoonanan","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.jtct.2025.01.002_bib0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ki.2012.169","article-title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C","volume":"82","author":"Schwartz","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtct.2025.01.002_bib0036","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.ajkd.2006.04.085","article-title":"Derivation and validation of cystatin C-based prediction equations for GFR in children","volume":"48","author":"Zappitelli","year":"2006","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.jtct.2025.01.002_bib0037","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.3390\/curroncol30030253","article-title":"Kidney injury in children after hematopoietic stem cell transplant","volume":"30","author":"James","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0038","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0039","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.01.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101054","article-title":"Chronic graft-versus-host disease in pediatric patients: differences and challenges","volume":"60","author":"Haroun","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2025.01.002_bib0041","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00277-018-3577-1","article-title":"Cyclosporine levels >\u2009195 \u03bcg\/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Bianchi","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.01.002_bib0042","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41409-022-01598-6","article-title":"Optimized cyclosporine starting dose may reduce risk of acute GVHD after allogeneic hematopoietic cell transplantation: a single-center cohort study","volume":"57","author":"H\u00e9ritier","year":"2022","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.jtct.2025.01.002_bib0043","article-title":"Hematopoietic stem cell transplantation and acute kidney injury in children: a comprehensive review","volume":"21:12935","author":"Raina","year":"2017","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0044","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41409-023-02136-8","article-title":"AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients","volume":"59","author":"Kim","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.002_bib0045","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.tp.0000229473.95202.50","article-title":"Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients","volume":"82","author":"San Segundo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2025.01.002_bib0046","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.002_bib0047","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","article-title":"Survival of acute myeloid leukemia cells requires PI3 kinase activation","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.002_bib0048","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"R\u00e9cher","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.002_bib0049","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2014.123","article-title":"Feedbacks and adaptive capabilities of the PI3K\/Akt\/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis","volume":"28","author":"Bertacchini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.01.002_bib0050","doi-asserted-by":"crossref","first-page":"52269","DOI":"10.18632\/oncotarget.13699","article-title":"The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed\/refractory acute myeloid leukemia: a phase Ib\/II study","volume":"8","author":"Tan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2025.01.002_bib0051","doi-asserted-by":"crossref","first-page":"e27062","DOI":"10.1002\/pbc.27062","article-title":"Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Place","year":"2018","journal-title":"Pediatr Blood Cancer"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672500003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672500003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:02:01Z","timestamp":1743498121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672500003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S266663672500003X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.002","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus with or without Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Children with Acute Kidney Injury: A Single-Center Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}